Article

Developing Nations and the Compulsory License: Maximizing Access to Essential Medicines While Minimizing Investment Side Effects

University of Connecticut School of Business, USA.
The Journal of Law Medicine &amp Ethics (Impact Factor: 0.94). 02/2009; 37(2):209-21. DOI: 10.1111/j.1748-720X.2009.00366.x
Source: PubMed

ABSTRACT This manuscript addresses how developing countries can maximize access to essential medicines and minimize unwanted side-effects within the legal environment of a compulsory license regime. While compulsory licensing can play a role in improving public health, external social and political conditions must be considered in order to make licensing an effective practice.

0 Bookmarks
 · 
216 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Much of today’s international trade is conducted according to trade agreements that involve substantial and uniform protections of intellectual property rights. Intellectual property rights are a socio-economic tool that create a temporary monopoly for inventor firms and enable such firms to charge prices for their innovations that are many times higher than the marginal cost of production of the innovations. This allows the inventor firms to salvage their research-costs and secure a profit on their innovations. A large body of contemporary philosophical and interdisciplinary literature suggests that intellectual property rights give rise to a number of ethical problems. This review paper seeks to give an overview of what these problems are. It also offers an outline of proposals as to how these problems might be alleviated, and it briefly explains the two classical defenses of the ethical permissibility of intellectual property rights. The ethical issues surrounding intellectual property rights are most pertinent when it is socially valuable goods that are given intellectual property protection. The discussions in this paper revolve around just one product type in order to bring out the broader ethical issues surrounding intellectual property rights. In line with much contemporary literature on the ethical dimensions of intellectual property rights, the product type in question is life-saving medicines.
    Philosophy Compass 12/2010; 5(12). DOI:10.1111/j.1747-9991.2010.00358.x
  • [Show abstract] [Hide abstract]
    ABSTRACT: Access to essential medications is limited in many low-to-middle income countries (LMICs) and those that are available may be prohibitively expensive to the general population. Clinical trials have been suggested as an approach to improve drug access in LMICs but the number of trials conducted in these countries is small because of regulatory issues and a lack of infrastructure. In this article, Nature Reviews Nephrology asks three experts their opinions on how to improve drug access and increase the numbers of clinical trials conducted in LMICs.
    Nature Reviews Nephrology 02/2015; DOI:10.1038/nrneph.2015.6 · 7.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Providing access to medicines and health care is one of the most challenging issues facing society today. In this paper the author highlights some of the complexities of the health value chain as well as the problems that the world's poor have in terms of access to medical care and medicines. He then attempts to delineate the roles and responsibilities of all stakeholders in order to define the specific corporate responsibili-ties of pharmaceutical companies in the context of the entire responsibility system— the strength of which is determined by its weakest link. Finally, he looks forward to a transformational change being wrought for pro-poor health development by forging new coalitions that cut across both the health and traditional development stakeholders.